Trial Profile
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2018
Price :
$35
*
At a glance
- Drugs Dapatifagene navolactibac (Primary)
- Indications Stomatitis
- Focus Adverse reactions
- Sponsors ActoGeniX
- 23 Mar 2018 Results presented in the Oragenics Inc media release.
- 21 Nov 2016 Results published in an Oragenics media release.
- 25 Oct 2014 New trial record